Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Commercializing nanodroplet technology to improve diagnostic sensitivity for difficult-to-lyse microbial samples

Award Number: SB1AI197360
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/20/2026
PERIOD OF PERFORMANCE END DATE: 06/30/2029

Group Awards By:

View Award Description

Commercializing nanodroplet technology to improve diagnostic sensitivity for difficult-to-lyse microbial samples - Abstract Triangle Biotechnology is developing SnapLyse™, a novel and proprietary technology for efficient, high- throughput, reproducible, and unbiased microbial lysis, based on a cavitation-enhancing nanodroplet reagent for use with low-power sonication devices. Efficient DNA extraction is required for successful and accurate identification of microorganisms or populations of microbes using nucleic acid testing (NAT) and next-generation sequencing (NGS) methods. Microbes with thick and resilient cell walls are particularly difficult to lyse using traditional chemical, enzymatic, and bead-beating based techniques. Poor DNA extraction from clinical and environmental samples containing resilient microbes lead to inconclusive or inaccurate diagnostic results. The current solution to this problem is primary culturing to isolate microbial strains for DNA extraction; however, culturing is economically and logistically unsustainable and presents with biological issues that confound results. Triangle Bio’s nanodroplet technology will address the clinical need for improvement in lysis and extraction methods from direct samples for NGS-based diagnostics and characterization of infectious diseases. This technology incorporates pre-formed cavitation nuclei requiring low levels of acoustic energy to release localized shockwave- and microstream-generated mechanical forces. SnapLyse nanodroplets incorporate a targeting ligand that binds to the microbial cell surface to deliver mechanical force to the pathogen. This design enables DNA extraction from low cell concentrations, and unbiased extraction from microbiome community samples. SnapLyse was used to improve the efficacy of culture-free, targeted next-generation sequencing for the identification of drug-resistant Mycobacterium tuberculosis (DR-Mtb); a Mtb-specific SnapLyse formulation was developed and was shown to improve the culture-free detection of DR-Mtb. This Commercialization Readiness Program project will advance Triangle’s platform through the following Specific Aims: 1. Optimize workflows for use with sputum, saliva, and stool, ensuring robust DNA extraction across diverse sample types and integrate with GenoScreen Deeplex Myc-TB and AmPORE-TB assays to provide a complete end to end diagnostic pipeline for Mtb; 2. Manufacturing scale-up and cost-optimization in preparation for commercial launch; and 3. Independent third-party clinical validation by Rapid Research in Diagnostics Development for Mtb (R2D2 TB) and preparation for FDA regulatory submission for SnapLyse.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $1,000,000 )
2026	2026	TRIANGLE BIOTECHNOLOGY, INC	303 W BARBEE CHAPEL RD	CHAPEL HILL	NC	27517	ORANGE	USA	Allergy and Infectious Diseases Research	000	1	7/20/2026	NEW	$1,000,000
														Subtotal = $1,000,000

Grand Total All Awards = $1,000,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Commercializing nanodroplet technology to improve diagnostic sensitivity for difficult-to-lyse microbial samples

Award Number: SB1AI197360

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/20/2026

PERIOD OF PERFORMANCE END DATE: 06/30/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer